Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

Patients with prior allogeneic stem cell transplant (alloSCT) are typically excluded from trials of chimeric antigen receptor (CAR) T cell therapies, because their engineered cells may include allogeneic T cells. Ciltacabtagene autoleucel (cilta-cel) demonstrated early, deep, durable responses and manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients. We retrospectively analyzed patients who received alloSCT prior to cilta-cel in CARTITUDE-1.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 22, 2023 Category: Hematology Authors: Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesus G Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu-min Yeh, Xiaoying Xu, Lida Pacaud, Muhammad Akram, Sundar Jagannath Tags: Original Study Source Type: research